Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers Sells 23,030 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 23,030 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $45.97, for a total value of $1,058,689.10. Following the completion of the transaction, the chief financial officer now directly owns 164,750 shares in the company, valued at approximately $7,573,557.50. This represents a 12.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

James William Rogers also recently made the following trade(s):

• On Tuesday, February 18th, James William Rogers sold 31,780 shares of Tempus AI stock. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40.
• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total transaction of $588,669.84.

Tempus AI Stock Performance

Shares of TEM opened at $48.03 on Thursday. The business’s 50 day moving average is $55.86 and its 200 day moving average is $51.48. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the stock. Kovitz Investment Group Partners LLC bought a new stake in shares of Tempus AI in the third quarter worth about $1,367,000. China Universal Asset Management Co. Ltd. purchased a new position in Tempus AI during the 4th quarter valued at approximately $1,091,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Tempus AI in the 4th quarter worth approximately $178,000. Captrust Financial Advisors bought a new stake in Tempus AI in the 3rd quarter worth approximately $2,726,000. Finally, abrdn plc bought a new position in shares of Tempus AI during the 4th quarter valued at approximately $2,784,000. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TEM. Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Piper Sandler decreased their target price on Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Guggenheim reissued a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Finally, Bank of America lifted their price objective on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.